Key Takeaway: Sanofi has published an update concerning its total number of voting rights and shares as of April 30, 2025. The report indicates that the number of issued shares stands at 1,226,230,828, with a real voting rights total of 1,348,348,742 and a theoretical voting rights number of 1,359,092,889. This disclosure complies with regulations set forth by French financial authorities, emphasizing the company's commitment to transparency in corporate governance.
Price reaction · baseline $49.21 (2025-05-14 close) · hit after-hours · clean, no other SNY news in the window
day 0 close · peak
+3.4%
Market Sentiment Analysis
POSITIVE FACTORS
Sanofi provides transparent information about its shares and voting rights.
The company maintains a substantial registered capital of over €2.45 billion.
The reported increase in the number of voting rights may indicate strong shareholder engagement.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+11%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
teplizumab/mL
Phase 2 · Diabetes Mellitus, Type 1
Full Press Release Details
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
a French société anonyme with a registered share capital of €2,452,461,656
Registered office : 46, avenue de la Grande Armée - 75017 Paris - France
Registered at the Paris Commercial and Companies Registry under number 395 030 844
Date
Total number of issued shares
Number of real voting rights (excluding treasury shares)
Theoretical number of voting rights (including treasury shares)*
30 April 2025
1,226,230,828
1,348,348,742
1,359,092,889
* Pursuant to 223-11 of the Règlement général de l’Autorité des Marchés Financiers.
This information is also available on the internet website of sanofi under « Regulated Information in France »: